WEDNESDAY, Sept. 7 (HealthDay News) ? Treating rheumatoid
arthritis (RA) patients with tumor necrosis factor (TNF) inhibitors
appears to increase their risk of developing skin cancer, a new review of
prior research indicates.
However, TNF inhibitors, which include infliximab (Remicade),
adalimunab (Humira), and etanercept (Enbrel), do not appear to boost the
risk for developing other forms of cancer, the researchers added.
The findings stem from an analysis of 21 previous studies conducted
between 1998 and 2010, as well as eight study summaries that had been
presented at research conferences during the same timeframe. All the
studies had focused on the potential for cancer risk in association with
the use of standard TNF inhibitors.
?This systematic review and meta analysis provides reassurance to
physicians and patients that the treatment of [rheumatoid arthritis] with
TNF inhibitors does not increase the risk of malignancy, particularly
lymphoma,? the French study team said in a news release from Annals of
the Rheumatic Diseases, which published the report in its current
online issue.
?However, it does appear to increase the risk of skin cancer, including
melanoma,? added the French team, led by Prof. Xavier Mariette from
Paris-Sud University?s rheumatology service in Ile de France.
The authors noted that RA has previously been shown to increase the
risk for developing certain types of cancer, including both lung cancer
and lymphoma, while decreasing the risk for other cancers, including bowel
and breast.
However, the question of TNF inhibitor treatments as a cancer risk has
remained a subject of debate.
All told, the current review looked at a collection of studies
involving more than 40,000 patients who had been exposed to nearly 150,000
years of TNF inhibitor drugs.
Seven of the studies indicated no notable risk increase for any type of
cancer associated with the use of TNF meds. Another two long-term studies
similarly suggested that while RA patients who had previously had cancer
faced a higher likelihood for a second bout, TNF treatments alone posed no
additional cancer risk.
But four other studies collectively demonstrated that TNF inhibitors
boosted the risk for non-melanoma skin cancer by 45 percent. And another
two studies suggested that the RA treatment raised the specific risk for
developing melanoma by nearly 80 percent.
Dr. W. Hayes Wilson, chief of rheumatology at Piedmont Hospital in
Atlanta, said the findings should help guide physicians on potential RA
treatment complications.
?I don?t think this is particularly surprising, given that there?s long
been a concern about cancer risk in the back of our minds,? he noted.
?And, in fac,t this is somewhat reassuring on the front of solid cancers
that there?s nothing to be alarmed about.?
?But while we can perhaps now put aside our worries about other types
of cancers, this does give us some indication that we need to be vigilant
when it comes to skin cancer,? Wilson added. ?And we certainly need to
have a high index of suspicion if a patient has a skin abnormality, and
make certain that they see their dermatologist.?
More information
For more on rheumatoid arthritis, visit the National Institutes of Arthritis and Musculoskeletal and
Skin Diseases.
Article source: http://news.yahoo.com/tnf-treatment-rheumatoid-arthritis-boosts-skin-cancer-risk-231405823.html
burkina faso elmo today show aesop alyson hannigan dirt 3 la fitness
কোন মন্তব্য নেই:
একটি মন্তব্য পোস্ট করুন